Targeted treatment of HCC revealed that the combined use of COX‐2 inhibitors with sorafenib showed a synergistic inhibitory effect on tumor growth and angiogenesis in mice bearing HCC xenografts.68 The gene discussed is PTGER2; the disease is hepatocellular carcinoma.